Experimental immune therapy aims to tackle HPV cancers before standard care
NCT ID NCT05639972
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced HPV-positive cancers of the cervix, throat, anus, or other sites. The goal is to see if this approach is feasible and safe, and whether it improves tumor response and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
E7 TCR-T cells (a type of immune cell therapy) plus aldesleukin (a drug to boost immune response)
What this could lead to
If it works, this approach could shrink or eliminate HPV-related tumors before standard therapy, potentially improving long-term survival.
What could go wrong
This is a very early (Phase 1/2) feasibility study with only 15 participants. The treatment may cause serious side effects from the conditioning chemo or aldesleukin, and it may not shrink tumors effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••